A detailed history of Raymond James & Associates transactions in Grifols Sa stock. As of the latest transaction made, Raymond James & Associates holds 14,952 shares of GRFS stock, worth $94,197. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,952
Previous 10,919 36.94%
Holding current value
$94,197
Previous $126,000 21.43%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 22, 2024

BUY
$5.47 - $11.38 $22,060 - $45,895
4,033 Added 36.94%
14,952 $99,000
Q4 2023

Jan 16, 2024

SELL
$7.71 - $11.56 $129,959 - $194,855
-16,856 Reduced 60.69%
10,919 $126,000
Q3 2023

Oct 24, 2023

BUY
$8.91 - $10.91 $247,475 - $303,025
27,775 New
27,775 $253,000
Q2 2022

Aug 12, 2022

BUY
$10.6 - $13.28 $324,328 - $406,328
30,597 Added 225.81%
44,147 $524,000
Q1 2022

May 11, 2022

BUY
$10.37 - $12.73 $140,513 - $172,491
13,550 New
13,550 $158,000
Q3 2021

Nov 02, 2021

SELL
$14.07 - $17.3 $679,538 - $835,538
-48,297 Closed
0 $0
Q2 2021

Aug 11, 2021

BUY
$16.62 - $18.94 $466,756 - $531,910
28,084 Added 138.94%
48,297 $838,000
Q1 2021

May 14, 2021

SELL
$15.15 - $19.78 $1,242 - $1,621
-82 Reduced 0.4%
20,213 $349,000
Q4 2020

Feb 12, 2021

BUY
$16.86 - $19.67 $9,256 - $10,798
549 Added 2.78%
20,295 $374,000
Q3 2020

Nov 04, 2020

BUY
$15.4 - $20.16 $22,052 - $28,869
1,432 Added 7.82%
19,746 $343,000
Q2 2020

Jul 28, 2020

BUY
$18.24 - $21.45 $62,161 - $73,101
3,408 Added 22.86%
18,314 $334,000
Q1 2020

Apr 21, 2020

BUY
$16.28 - $25.63 $65,185 - $102,622
4,004 Added 36.73%
14,906 $300,000
Q4 2019

Feb 12, 2020

BUY
$19.57 - $23.52 $213,352 - $256,415
10,902 New
10,902 $254,000
Q1 2019

May 06, 2019

SELL
$18.01 - $20.11 $361,820 - $404,009
-20,090 Closed
0 $0
Q4 2018

Feb 11, 2019

BUY
$17.44 - $21.53 $151,204 - $186,665
8,670 Added 75.92%
20,090 $369,000
Q3 2018

Nov 14, 2018

BUY
$19.97 - $21.96 $228,057 - $250,783
11,420 New
11,420 $244,000

Others Institutions Holding GRFS

About Grifols SA


  • Ticker GRFS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 678,910,976
  • Market Cap $4.28B
  • Description
  • Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...
More about GRFS
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.